November 1, 2018
PolyAurum is pleased to announce its acceptance as a resident company of the Johnson & Johnson Innovation – JLABS (JLABS) JPOD @ Philadelphia, in the Pennovation Center, the University of Pennsylvania incubator located in Philadelphia, PA. PolyAurum has been at Pennovation Center since January of 2018. The JPOD @ Philadelphia provides the benefits of JLABS, including access to expertise and mentorship, a state-of-the-art communications facility, educational programs and exposure to potential investors.
“I am thrilled to be in the first cohort of companies accepted into the JPOD @ Philadelphia,” said Deb Travers, PolyAurum’s CEO. “Having spent most of my career in the pharmaceutical industry, I am very aware of Johnson & Johnson’s reputation of innovation and broad expertise. It will be very helpful for us to have that expertise available to PolyAurum as we move towards filing an Investigational New Drug JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS aims to help entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
PolyAurum is developing biodegradable gold nanoparticles for use in diagnosing and treating patients with solid tumors. The gold nanoparticles selectively accumulate in a tumor and aim to significantly amplify the effect of radiation therapy in the tumor, while sparing the adjacent healthy tissues the side effects associated with a higher dose of radiation. These side effects can be life-altering or life-threatening and often result in therapy being scaled back or discontinued. This can result in disease progression and death. PolyAurum’s proprietary technology has the potential of improving survival and quality of life for these patients. For more information: http://polyaurum.com